	Application No.	Applicant(s)
Notice of Allowability	10/716,823	SACKEYFLO ET AL.
	Examiner	Art Unit
	Konata M. George	1616
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to <u>amendment filed March 12, 2007</u> .		
2. The allowed claim(s) is/are <u>5-42 and 44-64</u> .		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements 		
noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5. Notice of Informal P	atent Application
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	6. Interview Summary	··
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Dat 7.	te
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material JUHANN RICHIES GROUP 1500	Other	ent of Reasons for Allowance

Art Unit: 1616

4.

DETAILED ACTION

Claims 5-42 and 44-64 are pending in this application.

Action Summary

- 1. The examiner acknowledges the cancellation of claims 1-4 and 43. Therefore, any and all objections and/or rejections directed to them are hereby withdrawn.
- 2. The rejection of claim 44 under 35 U.S.C. 102(b) as being anticipated over The International Journal of Dermatology is hereby withdrawn in view of applicants amendment to the claim.
- 3. The rejection of claims 44-58 under 35 U.S.C. 103(a) as being unpatentable over The International Journal of Dermatology is hereby withdrawn in view of applicants amendment to the claim.

Statement of Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious a composition comprising a tricyclic antidepressant selected from the group consisting of maprotiline, amoxapine, 8-hydroxyamoxapine, 7-hydroxyamoxpine, loxapine, 8-hydroxyloxapine, clomipramine, desipramine, trimipramine, nortrityline or protriptyline together with a corticosteroid as the sole active

ingredients. The closest prior art reference, The International Journal of Dermatology,

teach a composition comprising a corticosteroid (triamcinolone) and an antidepressant

/Control Number. 10/7 10,62

(doxepin HCl). It does not teach or suggest using the antidepressants as claimed or a method of treating an immunoinflammatory disorders comprising the corticosteroid and an antidepressant.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

5. Claims 5-42 and 44-64 are allowed.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is 571-272-0613. The examiner can normally be reached from 8:00AM to 6:30PM Monday to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann R. Richter, can be reached at 571-272-0646. The fax phone numbers for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Application/Control Number: 10/716,823

Art Unit: 1616

published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have question on access to the Private Pair system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Konata M. George Patent Examiner Art Unit 1616

Johann R. Richter

Supervisory Patent Examiner

Art Unit 1616